Research Article

Potential Mechanisms of Biejiajian Pill in the Treatment of Diabetic Atherosclerosis Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

Rong Zhu,1 Bingzhao Du,2 Jiayao Yuan,1 Shuxun Yan,3 Mingyi Shao,4 Feng Sang,5 Qian Bi,2 Zhongrui Wang,1 Qian Zhen,1 and Yu Fu2,3

1School of the First Clinical, Henan University of Chinese Medicine, Zhengzhou 450000, China
2Department of Science Research, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China
3Department of Endocrinology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China
4Department of Gastroenterology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China
5Department of Key Laboratory of Viral Diseases Prevention and Treatment of Traditional Chinese Medicine of Henan Province, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China

Correspondence should be addressed to Yu Fu; kybfuyu@126.com

Received 8 January 2022; Revised 13 June 2022; Accepted 13 July 2022; Published 12 August 2022

Academic Editor: Lai Yen Fong

Copyright © 2022 Rong Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Biejiajian pill (BJJP), a classical traditional Chinese formula, has been reported that it has an effective treatment for diabetic atherosclerosis in recent years, but its underlying mechanisms remain elusive. The study aimed to explore the potential mechanisms of BJJP on diabetic atherosclerosis by integrating network pharmacology, molecular docking, and molecular dynamics simulation.

Methods. The active components of BJJP were collected by TCMSP and TCMID, and then the potential targets were obtained from the SwissTargetPrediction database. The targets related to diabetic atherosclerosis were identified from the GeneCards and OMIM databases. The intersection of the potential targets regulated by active components of BJJP and the targets of diabetic atherosclerosis were common targets, which were visualized by the Venn diagram. The common targets were imported into the STRING database to construct a protein-protein interaction (PPI) network. GO functional enrichment analysis and KEGG pathway enrichment analysis were performed using the DAVID database and visualized through bioinformatics. The intersecting targets were input into Cytoscape 3.7.1 software, and the Network Analyzer tool was employed to screen out the key targets. Then molecular docking was used to verify the binding affinity between the active compounds and the key targets, and molecular dynamics simulation was used to investigate the stability of the binding models. Results. A total of 81 active components, 186 targets of BJJP, and 4041 targets of diabetic atherosclerosis were obtained. Furthermore, 121 overlapping targets were identified. GO functional enrichment analysis revealed that these targets were correlated with the oxidation-reduction process, negative regulation of apoptotic process, inflammatory response, and other biological processes. The results of the KEGG pathway enrichment analysis showed that the common targets mainly participated in proteoglycans in cancer, PPAR signaling pathway, adherens junction, insulin resistance, HIF-1 signaling pathway, PI3K-Akt signaling pathway, etc. The results of molecular docking confirmed that the core active components in BJJP could bind well to the key targets. Results from molecular dynamics simulation showed that the binding energies of AKT1-Luteolin, MMP9-quercetin, and MMP9-luteolin complexes were $-28.93 \text{ kJ/mol}$, $-37.12 \text{ kJ/mol}$, and $-62.91 \text{ kJ/mol}$, respectively. Conclusion. The study revealed that BJJP is characterized as multicomponent, multitarget, and multipathway to treat diabetic atherosclerosis, which is helpful to provide ideas and a basis for pharmacological research and clinical application in the future.
1. Introduction

Diabetes mellitus has emerged as a pandemic. The International Diabetes Federation (IDF) has released new figures showing that 537 million adults are now living with diabetes worldwide, which is a rise of 16% (74 million) since the previous IDF estimates in 2019 [1]. The increased incidence rate is projected to continue as greater numbers of people adopt an unhealthy lifestyle [2]. Atherosclerosis is an important complication of diabetes and the leading cause of mortality in patients with diabetes [3]. Compared with nondiabetics, atherosclerosis in diabetic patients has the characteristics of high incidence, young age of onset, rapid disease progression, and multiple organs involved simultaneously [4]. This has emphasized the importance and urgency of studying the mechanism of diabetic atherosclerosis and exploring therapeutic options.

Biejiajian pill (BJJP) originated from Synopsis of Golden Chamber, a traditional Chinese medicine clinical prescription, is broadly utilized for the prevention and therapy of hepatocellular carcinoma [5], so the research on BJJP mainly focused on digestive disease. In recent years, some studies have found that BJJP has a significant effect on diabetic atherosclerosis. A randomized control method was used to find that BJJP can raise blood flow velocity in the lower limb, reduce low serum density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triglyceride (TG) levels, and improve the clinical symptoms of lower limb pain and numbness in lower extremity arteriosclerosis obliterans of diabetic patients [6]. Furthermore, previous studies have shown that BJJP has the effects of protecting vascular endothelial cells (VECs), inhibiting the proliferation and migration of vascular smooth muscle cells (VSMCs), and stabilizing plaques in diabetic atherosclerosis rats. The therapeutic potential may be achieved through regulating blood lipids, reducing inflammatory factors, lowering serum endothelin-1 (ET-1), increasing serum nitric oxide (NO) levels, reducing the expression of matrix metalloproteinases-9 (MMP-9) in aortic intima, and elevating APN-mRNA expression levels in adipose tissue [7–9]. However, its underlying mechanisms are not very clear, so it is necessary to explore the biological basis.

Diabetic atherosclerosis is a disease with a complex pathological mechanism and its potential mechanism remains elusive. At present, lifestyle interventions, antihyperglycemia, antihypertension, lipid regulation, and antiplatelet therapy are widely adopted in clinics, but single-targeted therapy cannot meet the needs of inhibiting the occurrence and development of diabetic atherosclerosis. Therefore, it is crucial that safer and more effective drugs are needed for the treatment of diabetic atherosclerosis.

Network pharmacology provides new horizons for traditional Chinese medicine (TCM) formula research. Its comprehensiveness, systematicness, and holistic concept are consistent with the TCM formula’s characteristics of multicomponent, multitarget, and multipathway. Most TCM formula prescriptions were derived from empiricism. It lacks scientific and rational mechanism interpretation although its efficacy has been validated for many years in clinical practice. The application of network pharmacology in the TCM formula is expected to achieve the change from experience-based medicine to evidence-based medicine, and network pharmacology is expected to become an important direction of TCM research studies [10].

In this study, network pharmacology analysis, molecular docking techniques, and molecular dynamics simulation were used to visualize and elucidate the complex relationships and underlying mechanisms of BJJP in the treatment of diabetic atherosclerosis, which is helpful to provide a reference for experimental studies and clinical application in the future. The detailed flowchart of this study is summarized in Figure 1.

2. Materials and Methods

2.1. Screening of Active Compounds and Prediction of Corresponding Targets of BJJP. The active compounds of BJJP were acquired from the Traditional Chinese Medicine Systems Pharmacology database and Analysis Platform (TCMSP, http://tcmsp.com/tcmsp.php) [11] with the standards of oral bioavailability (OB) ≥ 30% and drug-likeness (DL) ≥ 0.18 and the Traditional Chinese Medicines Integrated Database (TCMID, http://47.100.169.139/tcmid/) [12] with the standards of the following two conditions simultaneously: firstly, GI absorption (gastrointestinal absorption) was “High”; secondly, two of the top five items of drug-likeness (including Lipinski, Ghose, Veber, Egan, and Muegge) were “Yes.” In addition, according to the published interrelated literature on compounds, the active compounds of unpredictable medicines were supplemented. Subsequently, the normalized name, PubChem CID, and the SDF structure format of the 2D structure of every active compound were obtained in the PubChem database (https://pubchem.ncbi.nlm.nih.gov) [13]. The targets were predicted by the SwissTargetPrediction database (http://www.swisstargetprediction.ch/) [14] and the related targets belonging to “Home sapiens” and “probability > 0.3” were chosen.

2.2. Construction of Medicine-Compound-Target Network. In order to more intuitively show the interactions between the active compounds of BJJP and their potential targets, the “medicine-compound-target” network was constructed by Cytoscape 3.7.1 software [15].

2.3. Screening of the Targets of Diabetic Atherosclerosis and Getting the Common Targets. The keyword “diabetic atherosclerosis” was used to extract the targets from the GeneCards (https://www.genecards.org/) [16] and Online Mendelian Inheritance in Man (OMIM, https://omim.org/) [17] databases. The targets of diabetic atherosclerosis belonging to “Homo sapiens” were integrated after deleting the repeated genes. A Venn diagram was drawn to get the overlapping targets between the drug targets and the disease targets.
2.4. Construction of the Protein-Protein Interaction (PPI) Network and Screening of the Key Targets. In general, it is difficult for a single protein to complete a series of complex biological processes. The common targets of BJJP and diabetic atherosclerosis were imported to the Search Tool for the Retrieval of Interacting Genes (STRING) database (https://string-db.org) [18] with the species limited to "Homo sapiens." The information of target interaction was imported into Cytoscape 3.7.1 software, and the Network Analyzer tool was employed for topology analysis to screen overlapping targets. The key targets were further analyzed using KEGG and GO enrichment analysis, molecular docking, and molecular dynamics simulation.

Figure 1: The flowchart of this study based on network pharmacology, molecular docking, and molecular dynamics simulation for deciphering the potential mechanisms of BJJP against diabetic atherosclerosis.
out the key targets. The higher the degree, the larger the node and the coarser the edge, indicating a stronger relationship.

2.5. Gene Ontology (GO) Functional Enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Enrichment Analysis. The common targets were imported into the Database for Annotation Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov/) [19] for bioinformation enrichment analysis, including biological process (BP), cellular component (CC), molecular function (MF), and KEGG pathway enrichment analysis. The GO terms and KEGG pathway terms with P value <0.05 were considered significant entries. A histogram was constructed with the first 10 functional categories of BP, CC, and MF. A bubble diagram was drawn by the top 20 signal pathways, and then the information of the first 20 pathways was imported into Cytoscape 3.7.1 software to display the "target-pathway" network.

2.6. Molecular Docking. The 3D structures of the key targets were retrieved and downloaded from the RCSB Protein Data Bank (https://www.rcsb.org/) [20], removing the ligands and water in PyMOL software [21], and the PDBQT formats were converted by AutoDock Tools1.5.6 software [22]. After that, utilize the AutoDock Vina to perform the molecular docking and get the docking scores. Visualization of the docking results was carried out on PyMOL software. Affinity could evaluate the binding capacity between the core active compounds and the targets. The affinity $< -4.25$ kcal/mol indicated that the compound could bind and interact with the target, whereas the affinity $< -5.0$ kcal/mol demonstrated good binding activity and the affinity $< -7.0$ kcal/mol demonstrated a strong binding force [23].

2.7. Molecular Dynamics Simulation. The docking models of the complexes on the top three molecular docking results were used as the initial conformation for molecular dynamics (MD) simulations. The force fields of the receptor were set to Amberff99SB using pdb2gmx in GROMACS v4.6.5 [24, 25]. Similarly, the force fields of the ligand were set to GAFF (general amber force field) using AmberTools 18 software [26, 27]. The complex systems were preprocessed by the following steps: firstly, the TIP3P water molecules solving the system with the dodecahedron box; secondly, Na$^+$ and Cl$^-$ neutralizing the system; and thirdly, the periodic boundary condition with a minimal distance of 1.2 nm. The steepest descent minimization method was applied to the energy minimization of complex systems. Meanwhile, 100 psNVT and NPT simulations were implemented to sequentially balance the complex systems. Furthermore, the PME (Particle Mesh Ewald), LINCS (Linear Constraint Solver), and SETTLE algorithms were performed to calculate the long-range electrostatic interactions, constrain hydrogen bonds, and restrict water molecules, respectively.

3. Results

3.1. Screening of the Active Compounds and Related Targets. A total of 81 active compounds in BJJP were screened via TCMS and TCMID databases and the published related literature. The basic information of active ingredients is listed in Table S1 (Additional file 1). Then 186 related targets were predicted with the condition of “Homo sapiens” and “probability > 0.3” in the SwissTargetPrediction database.

3.2. The Network of Medicine-Compound-Target. To further reflect the interaction relationship between the active compounds and their targets, the network of medicine-compound-target was constructed through Cytoscape 3.7.1 software. The blue diamond nodes represented the targets, the green circle nodes represented Chinese medicine, and the octagon nodes represented the active compounds as shown in Figure 2.

3.3. Screening of the Targets Related to Diabetic Atherosclerosis and Getting the Common Targets. For disease target identification, 3865 and 227 targets of “diabetic atherosclerosis” were identified from the GeneCards and OMIM databases, respectively. Subsequently, 4041 disease targets were integrated after deleting duplicates. Finally, 121 overlapping targets were shown as a Venn diagram between the drug targets and the disease targets (Figure 3).

3.4. Construction of PPI Network and Determination of the Key Targets. The PPI network was constructed with a medium confidence score of 0.4 by importing the common targets into the STRING database, as shown in Figure 4(a). The network consisted of 121 nodes and 797 edges with an average node degree value of 13.2. Then the results after analysis were imported into Cytoscape 3.7.1 software. The degree values of common targets were computed through topological analysis and represented the interaction relationship between targets. The nodes of size and color were set according to their degree value and the size of nodes changing from big to small and the color from red to purple represented the degree from high to low, as shown in Figure 4(b). Ultimately, the top nine degree targets (AKT1, EGFR, SRC, STAT3, PPARG, ESR1, MMP9, PIK3R1, and AR) were identified as the key target proteins for further analysis.

3.5. GO and KEGG Enrichment Analysis. GO function enrichment included BP, CC, and MF. Among them, 205 items were obtained via BP enrichment analysis, 31 items via CC, and 84 items via MF. The BP analysis indicated that the overlapping targets were mainly related to signal transduction, positive regulation of transcription from RNA polymerase II, oxidation-reduction process, negative regulation of the apoptotic process, inflammatory response, etc. The CC results mainly included plasma membrane, cytosol, extracellular space, protein complex, etc. The MF results are mainly comprised of enzyme binding, protein kinase
activity, steroid binding, etc. The top 10 items of BP, CC, and MF were selected to draw the GO function histogram of BJJP in the treatment of diabetic atherosclerosis (Figure 5(a)). Meanwhile, the results of the KEGG analysis showed 63 pathways with a threshold value of $P < 0.05$ and a bubble diagram was drawn by the top 20 signal pathways. The larger the bubble, the more genes were gathered in the pathway. As depicted in Figure 5(b), the KEGG pathways of BJJP against diabetic atherosclerosis were mainly related to the PPAR signaling pathway, prolactin signaling pathway, adherens junction, insulin resistance, HIF-1 signaling pathway, and so on. In order to illuminate the correlation between the top 20 signal pathways and their targets, the network of targets-pathways was constructed, the purple nodes represented the targets, and the green represented the pathways (Figure 5(c)).

3.6. The Results of Molecular Docking. Molecular docking and binding ability prediction were carried out with five core active compounds (including quercetin, luteolin, kaempferol, chrysin, and glutamic acid) and nine key targets (AKT1, EGFR, SRC, STAT3, PPARG, ESR1, MMP9, PIK3R1, and AR), respectively. Finally, 45 groups of ligand-receptor docking results were obtained, 44 with affinity $< -4.25 \text{ kcal/mol}$. The results of the molecular docking indicated most of the core active compounds could bind well with key targets and there were stable hydrogen bonds at the binding sites. A section of the docking patterns of the core compounds and targets are shown in Figure 6(a). The molecular docking scores is shown in Figure 6(b). The color from light to dark represented the binding ability from weak to strong. The results of molecular docking could provide data support for further experimental design of related traditional Chinese formulas or compounds. A portion of the binding affinity and the number of hydrogen bonds were shown in Table 1.

3.7. The Results of MD Simulation. The MD simulations of the AKT1-luteolin, MMP9-quercetin, and MMP9-luteolin complexes were implemented to investigate the stability of the binding models. From Figure 7(a), it was observed that the AKT1-luteolin complex has already reached equilibrium at about 50 ns with 4.0 Å RMSD. From Figures 7(b) and 7(c), it was seen that MMP9-quercetin and MMP9-luteolin complexes have already reached equilibrium at about 50 ns

![Drug targets and Disease targets](image)
and 70 ns with 2.5 Å and 3.0 Å RMSD, respectively. These results suggested that luteolin could bind efficiently to AKT1 and MMP9 and quercetin could bind well to MMP9.

Meanwhile, the binding energies of these complexes were calculated using the MM/PBSA method. From Table 2, the binding energies of AKT1-luteolin, MMP9-quercetin, and MMP9-luteolin complexes were $-28.93 \text{kJ} \cdot \text{mol}^{-1}$, $-37.12 \text{kJ} \cdot \text{mol}^{-1}$, and $-62.91 \text{kJ} \cdot \text{mol}^{-1}$, respectively, showing that the binding processes were spontaneous. In addition, it also implied that luteolin was more likely to bind to MMP9 compared to quercetin, which was consistent with the docking result.

Then, the binding energies of these complexes were decomposed to each residue. From Figure 7(d), it was observed that residues Glu169, Lys170, Thr172, Gly173, Thr433, and Thr435 were helpful for binding between AKT1 and luteolin, while residues Glu151, Lys168, and Arg174 were the opposite. From Figure 7(e), it was found that residues Asp113, Glu174, His226, Tyr248, Glu252, and Gly269 played a significant role in the binding process between quercetin and MMP9. From Figure 7(f), it was seen that residues Asp182, Asp185, Leu188, Glu208, Val223, His226, Tyr248, and Arg249 were beneficial to the binding process between luteolin and MMP9.

4. Discussion

Diabetes mellitus (DM) is a chronic disease that occurs when the pancreas is no longer able to make insulin or when the body cannot make good use of the insulin it produces. People with diabetes have an increased risk of developing a number of serious health problems. Notably, macrovascular complications are the leading cause of disability and death in patients with diabetes mellitus, and the injury of VECs is the initiating factor and the key link. Previous studies have shown that BJJP has a significant effect on diabetic atherosclerosis. However, the underlying mechanisms of BJJP against diabetic atherosclerosis are not fully elucidated. In this study, we employ the technology of network pharmacology, approaches of molecular docking, and MD simulation to explore the potential mechanisms of BJJP on diabetic atherosclerosis in order to better guide clinical treatment.

Firstly, we retrieved the active compounds of BJJP, and 81 were identified. Then we constructed the medicine-compound-target network by mapping 81 active compounds to 186 related targets. Notably, the top five active compounds with high degree value are quercetin, luteolin, kaempferol, chrysin, and glutamic acid, respectively, indicating that they may be the core bioactive compounds. Among them, quercetin, luteolin, kaempferol, and chrysin all belong to flavonoids, which exist widely in nature, and have the function of both medicine and food and a wide range of pharmacological activities. They all show antioxidative and anti-inflammatory effects; however, the mechanisms are not exactly the same. To some extent, these were associated with the pathogenesis of diabetic atherosclerosis. It has been reported that quercetin may have promising potential in ameliorating diabetic atherosclerotic pathophysiology in the diabetic-induced atherosclerotic rat model carotid artery induced by the administration of a high-fat diet with streptozotocin by inhibiting oxidative stress and inflammatory responses mechanistically by modulating the AMPK/SIRT1/NF-κB signaling pathway [28]. Luteolin and chrysin can combine with the hydrogen atom of the phenolic hydroxyl group to form the free radical of flavonoid, which can play the role of antioxidation. At the same time, it showed a better anti-inflammatory effect [29]. VSMC proliferation and migration, as well as endothelial cell apoptosis, are important processes that participate in the pathogenesis of diabetic atherosclerosis. Luteolin can inhibit proliferation and migration in VSMCs through down-regulation of the PI3K/Akt signaling pathway in endothelial cells, regulating the MAPK signaling pathway and inhibiting the generation of reactive oxygen species (ROS) in order to inhibit the occurrence and development of diabetic atherosclerosis [30]. Kaempferol has been demonstrated to provide benefits for the treatment of atherosclerosis, coronary heart disease, hyperlipidemia, and diabetes through its antioxidant and anti-inflammatory properties by the
**Figure 5: Continued.**

(a)

- hsa05205: Proteoglycans in cancer
- hsa03320: PPAR signaling pathway
- hsa04917: Prolactin signaling pathway
- hsa04520: Adherens junction
- hsa05200: Pathways in cancer
- hsa04931: Insulin resistance
- hsa04066: HIF-1 signaling pathway
- hsa04915: Estrogen signaling pathway
- hsa05162: Measles
- hsa05160: Hepatitis C
- hsa05221: Acute myeloid leukemia
- hsa04923: Regulation of lipolysis in adipocytes
- hsa04151: PI3K-Akt signaling pathway
- hsa04510: Focal adhesion
- hsa04012: ErbB signaling pathway
- hsa05219: Bladder cancer
- hsa05215: Prostate cancer
- hsa05214: Glioma
- hsa04662: B cell receptor signaling pathway
- hsa05218: Melanoma
inhibition of the ASK1/MAPK signaling pathway and the regulation of oxidative stress [31].

Metformin is currently recommended as a first-line treatment for patients with diabetes and as an essential drug in combination, in the guides of both domestic and international. Its main pharmacological effect is to reduce blood sugar by reducing the liver glucose output and improving insulin resistance. Metformin alone did not increase the risk of hypoglycemia and reduced the risk of cardiovascular events, but there were gastrointestinal adverse events [32]. Chrysin is one of the main components of Huangqin, and it could produce similar effects as metformin verified in nude diabetic mice models. It could decrease glucose and triglyceride levels and improve the generation of proinflammatory cytokines involved in the development of diabetes and its complications, such as diabetic atherosclerosis and other cardiovascular diseases [33]. In epidemiologic studies, abnormal metabolism of glutamic acids has been shown to be related to insulin resistance, type 2 diabetes, and cardiovascular disorders. Genetic locus associated among type 2 diabetic patients may affect the risk of coronary heart disease by affecting the metabolism of glutamic acids in endothelial cells.

Insulin resistance is closely associated with chronic low-grade inflammation through interactions with the insulin signaling pathway in the liver and adipose tissue, which is also considered one of the main factors responsible for the onset and progression of diseases such as obesity, diabetes, and atherosclerosis. Therefore, the improvement of insulin resistance is important in the management of diabetes atherosclerosis. The HIF-1 signaling pathway plays a key role in the development of atherosclerosis through cell-specific responses acting on endothelial cells, VSMCs, and macrophages. Through the upregulation of VEGF, NO, ROS, and PDGF, it is able to cause endothelial cell dysfunction, proliferation, angiogenesis, and inflammation [34]. It was also found that the TNF, PI3K/Akt, and MAPK signal pathways can interact with the HIF signal pathway, leading to the gradual progress of diabetes and its complications [35]. Therefore, the HIF-1 signaling pathway may be an effective way to treat diabetic atherosclerosis to a certain extent. The PPAR signaling pathway regulates glucose and lipid metabolism, endothelial function, and inflammation [36]. Peroxisome proliferator-activated receptors (PPARs) are a subgroup of the nuclear hormone receptor superfamily of ligand-activated transcription factors, which play an important role in the pathogenesis of type 2 diabetes mellitus (T2DM) and atherosclerosis. It has been reported that genetic disruption or pharmacological inhibition of the AT1R attenuates atherosclerosis and improves endothelial function in diabetic ApoE-/- mice via the PPAR pathway [37]. The functions of the prolactin receptor have been extended to include islet differentiation, adipocyte control, and immune modulation. Also, the prolactin signaling pathway disruption has been involved in diabetes. Meanwhile, prolactin has been suggested to stimulate the development of atherosclerosis and cardiovascular disease through its effects on metabolism and inflammation, and the inhibition of prolactin function may beneficially affect atherosclerosis burden [38]. Adherens junction is one of the aspects of the integrity of vascular endothelial function. A study showed that altering adherens junction phosphorylation levels can impair vascular endothelial permeability and affect the binding and dissociation of its components in high-glucose conditions, which will be helpful for understanding the process of arterial injury in diabetes patients and might open up new targets for therapeutic development [39].

In the PPI network, we found that AKT1 (degree = 70), EGFR (degree = 53), SRC (degree = 53), STAT3 (degree = 50), PPARG (degree = 45), ESR1 (degree = 44), MMP9 (degree = 37), PIK3R1 (degree = 29), and AR (degree = 29) played important roles in BJJP against diabetic atherosclerosis. It is well known that AKT1 is one of the three isoforms
Figure 6: Continued.
of the AKT family. AKT is one of the key molecules activated downstream of the PI3kinase signaling pathway and regulates many cellular processes including metabolism, proliferation, cell survival, growth, and angiogenesis through serine and/or threonine phosphorylation of a range of downstream substrates. However, one of the key roles of AKT is the regulation of glucose uptake into insulin-responsive tissues, which is mediated by the translocation of insulin-regulated glucose transporter 4 (GLUT4) from vesicular intracellular compartments to the plasma membrane [40]. In addition, AKT also plays a role in the repression of liver gluconeogenesis by insulin by suppressing the expression of phosphoenolpyruvate carboxykinase and glucose 6-phosphatase in this process [41]. Nitric oxide (NO) is mainly produced by endothelial cells and acts as a vasodilator and inhibitor of smooth muscle cell migration and platelet activation, thereby protecting from vascular disease. Insulin is known to affect the vasculature by increasing the release of NO from endothelial cells through the PI3K/AKT pathway. The cells where AKT contributes to cardiovascular function are endothelial cells, which predominantly express AKT1 [42]. Genetically modified mice revealed the protective role of AKT1 in vascular function, with AKT1 KO mice on an ApoE-/- background displaying severe peripheral vascular disease, atherosclerosis, occlusive coronary artery disease, plaque vulnerability, and cardiac dysfunction. This manifested itself in decreased blood flow, reduced migration of fibroblasts and endothelial cells, and decreased production of the potent vasodilator NO [43, 44]. EGFR, which is distributed in all vascular epithelial cells, can interfere with cell growth, differentiation, and proliferation by participating in RAS/RAF/MEK/MAPK and PI3K/PDK1/AKT pathways. It is reported that enhanced EGFR phosphorylation and its downstream ER stress are involved in cardiac fibrosis and vascular endothelial dysfunction in type I diabetes mellitus [45]. SRC is a tyrosine-protein kinase that regulates cellular metabolism, survival, and proliferation. Studies have shown that SRC kinase plays an important role in RAGE-mediated inflammatory gene expression, migration in VSMCs, and key events associated with diabetic vascular complications [46]. Activation of signal transducers and activators of transcription (STAT) pathway by hyperglycemia and dyslipidemia contributes to the progression of diabetic atherosclerosis and other diabetic complications. Recio had proved inhibition of STAT1/STAT3 activation and target gene expression in VSMCs and macrophages could suppress cytokine-induced cell migration and adhesion processes [47]. PPARG could not only inhibit the expression of inflammatory factors such as TNF-α and IL-1 but also regulate adipocyte differentiation as well as lipid metabolism. This activity might contribute to the treatment of diabetic atherosclerosis [48]. Previously, an African-American case-control study detected an association between a region of the ESR1 gene and type 2 diabetes. Moreover, it appeared that ESR1 contributes to type 2 diabetes and CVD risk via pleiotropic effects, leading to insulin resistance, a poor lipid profile, and obesity [49]. MMP9 is a member of the metalloproteinase family and one of the most important enzymes involved in matrix metabolism. Matrix metalloproteinases (MMPs), a large family of zinc and calcium-dependent endopeptidases that degrade all components of the extracellular matrix and basement membrane proteins, are known to be closely associated with diabetic atherosclerosis. Inhibition of the IκB/NF-κB signal pathway via the MMP9/TIMP1 axis has an effect on vascular inflammation T2DM atherosclerosis [50]. It can also promote the consumption and rupture of fibrous cap and regulate the stability of plaque. It has been found that PIK3R1 can affect insulin signaling transduction and thus play a direct role in the development of diabetes through insulin resistance signaling [51]. Accumulating data emphasize the importance of AR on the expression in the key vascular tissues, including endothelial cells and VSMCs [52]. It was also verified that AR was crucial in

![Heat maps of the docking scores for active compounds and key targets.](image-url)

**Figure 6:** (a) Action modes of active compounds with key targets. (A) AKT1 and quercetin; (B) AKT1 and luteolin; (C) AKT1 and kaempferol; (D) SRC and quercetin; (E) SRC and luteolin; (F) SRC and kaempferol; (G) EGFR and luteolin; (H) EGFR and kaempferol; (I) STAT3 and quercetin; (J) STAT3 and luteolin. (b) Heat maps of the docking scores for active compounds and key targets.
Table 1: Docking affinity and relevant results of hub targets and key compounds.

| Compound     | Compound 2D structure | Target | PDB ID | Structure with initial ligand | Affinity (kcal/mol) | Amino acid residue                              | The number of hydrogen bonds |
|--------------|------------------------|--------|--------|-------------------------------|---------------------|------------------------------------------------|-------------------------------|
| Quercetin    |                        | AKT1   | 6HHF   |                               | −8.7                | ASP292, VAL271, GLN79                           | 3                             |
| Luteolin     |                        | AKT1   | 6HHF   |                               | −9.3                | THR211, THR291                                 | 2                             |
| Kaempferol   |                        | AKT1   | 6HHF   |                               | −8.7                | ILE290, ASP292, THR211                         | 3                             |
| Quercetin    |                        | SRC    | 4MXY   |                               | −7.9                | GLU310, ASP404, MET341, LEU273                  | 5                             |
| Luteolin     |                        | SRC    | 4MXY   |                               | −8.0                | GLU310, MET341, LEU273, ASP404, ASP354         | 4                             |
| Kaempferol   |                        | SRC    | 4MXY   |                               | −7.5                | MET341, GLU310                                  | 3                             |
| Luteolin     |                        | EGFR   | 3W2S   |                               | −8.7                | ASP855, MET793                                  | 2                             |
| Kaempferol   |                        | EGFR   | 3W2S   |                               | −8.2                | MET793                                          | 1                             |
| Quercetin    |                        | STAT3  | 6NJS   |                               | −6.2                | GLU638, GLN644, PRO639                          | 3                             |
| Luteolin     |                        | STAT3  | 6NJS   |                               | −6.2                | GLU638, GLN644                                  | 2                             |

Figure 7: (a–c) The RMSD of AKT1-luteolin, MMP9-quercetin, and MMP9-luteolin. (d–f) The residues energy decomposition of AKT1-luteolin, MMP9-quercetin, and MMP9-luteolin complex systems.
mediating the effects of androgens to regulate glucose and lipid metabolisms in males and relatively early coronary atherosclerosis [53].

In conclusion, the therapeutic potential of BJJP in the treatment of diabetic atherosclerosis may be through regulating blood lipids, reducing inflammatory factors and oxidation-reduction reaction, and so on.

Molecular docking and MD simulation were employed to further verify the results obtained. The results of the molecular docking indicated most of the core active compounds could bind well with key targets. Then the results of molecular dynamics simulation suggested that AKT1-luteolin, MMP9-quercetin, and MMP9-luteolin could bind tightly, and the binding energies of the complexes were $-28.93 \pm 0.79$, $-37.12 \pm 2.93$, and $-62.91 \pm 8.23$ kJ·mol$^{-1}$, respectively, showing that the binding processes were spontaneous.

However, it should be noted that there were certain limitations of the network pharmacology. Firstly, it is difficult for current network pharmacology technology to achieve the goal of quantizing, such as the dose-efficacy relationship between the drugs and disease [10]. Secondly, its network modeling is based on the information of the existing databases and existing experiments data; therefore, a part of the compounds and targets of insects are not found and included. Thirdly, the study based on network pharmacology is a static network analysis while the occurrence and development of disease and the action of drugs are both dynamic processes, so the following experiments in vivo or in vitro can be carried out on this basis to explore the deeper mechanism of BJJP in the treatment of diabetic atherosclerosis. Despite the limitations of this study, the results revealed the underlying mechanisms of BJJP against diabetic atherosclerosis, which had certain clinical value and research significance.

### 5. Conclusion

In conclusion, the study was based on network pharmacology, molecular docking, and MD simulation to explore the potential mechanisms of BJJP against diabetic atherosclerosis through compound screening, target prediction, construction of PPI network, GO enrichment analysis, and KEGG pathway enrichment analysis. The results indicated that quercetin, luteolin, kaempferol, chrysin, glutamic acids, and other effective compounds of BJJP showed therapeutic effects against diabetic atherosclerosis via multiple targets and multiple pathways. In addition, the good activities of the core active compounds and the key targets were verified by the molecular docking method and molecular dynamics simulation. All in all, the results of this study provided a reference for clinical application and guidance for further experimental verification of BJJP for the treatment of diabetic atherosclerosis.

### Data Availability

The data for this study can be provided by the corresponding author (Yu Fu: kybfuyu@126.com).

### Disclosure

Rong Zhu and Bingzhao Du are the co-first authors.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### Authors’ Contributions

RZ and BZD contributed equally to this study. YF conceived and designed the study. SXY, MYS, and FS guided the study. QB revised the manuscript. JYY, ZRW, and QZ retrieved the compounds and targets. RZ and BZD analyzed the data and wrote the draft of the paper. All authors have read and approved the final manuscript.

### Acknowledgments

This study was supported by the National Natural Science Foundation of China (no. 81704011), the China Postdoctoral Science Foundation (no. 2022M711085), the Special Scientific Research Project of National Traditional Chinese Medicine Clinical Research Base of Henan Provincial Health Commission (no. 2019J1DZX2026), and the Special Project for Traditional Chinese Medicine Science Research of Henan Province (no. 2022ZY1005).

### Supplementary Materials

Additional file 1: Table S1: basic information of part of active compounds of BJJP. (Supplementary Materials)

### References

[1] International Diabetes Federation, *IDF Diabetes Atlas*, International Diabetes Federation, Brussels, Belgium, 10th edition, 2021.

[2] J. A. Beckman and M. A. Creager, “Vascular complications of diabetes,” *Circulation Research*, vol. 118, no. 11, pp. 1771–1785, 2016.
[3] J. Tian, Y. Liu, L. Yue, K. Chen, and L. Shuzheng, "Cellular and molecular mechanisms of diabetic atherosclerosis: herbal medicines as a potential therapeutic approach," *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 9080869, 16 pages, 2017.

[4] M. Vigimaa, A. Sachinidis, M. Tournpourleka, K. Koutsampanopoulos, S. Alliksoo, and T. Titma, "Macrovascular complications of type 2 diabetes mellitus," *Current Vascular Pharmacology*, vol. 18, no. 2, pp. 110–116, 2020.

[5] J. Sun, W. Chen, B. Wen et al., "Biejiajian pill inhibits carcinogenesis and metastasis via the akt/GSK-3β/snail signaling pathway in hepatocellular carcinoma," *Frontiers in Pharmacology*, vol. 12, Article ID 610158, 2021.

[6] Y. C. Fan, *Clinical Study of Biejiajian Pill in the Treatment of Diabetes Mellitus Complicated with Arteriosclerosis Obliterans of Lower Extremities*, Henan University of Traditional Chinese Medicine, Zhengzhou, China, 2012.

[7] J. H. Han, Z. Li, H. Y. Yang, and Y. Fu, "Study on the effect of Biejiajian pill on adiponecingen in diabetic rats with atherosclerosis," *Liszichen Medicine and Materia Medica Research*, vol. 22, no. 4, pp. 1017–1018, 2011.

[8] J. H. Zai, J. H. Han, Z. Li, and Y. Fu, "Study on the effects of Biejiajian pill on inflammatory factors in diabetic rats with atherosclerosis," *Acta Chinese Medical*, vol. 26, no. 5, p. 3, 2011.

[9] Y. Fu, H. B. Yu, Z. Li, and J. H. Han, "Effects of Biejiajian Pills on blood lipids, vascular endothelial function, and matrix metalloproteinase-9 in rats with diabetes and atherosclerosis," *Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology*, vol. 5, p. 4, 2014.

[10] T. T. Luo, Y. Lu, S. K. Yan, X. Xiao, X. L. Rong, and J. Guo, "Network pharmacology in research of Chinese medicine formula: methodology, application and prospective," *Chinese Journal of Integrative Medicine*, vol. 26, no. 1, pp. 72–80, 2020.

[11] J. Ru, P. Li, J. Wang et al., "TCMSP: a database of systems pharmacology for drug discovery from herbal medicines," *Journal of Cheminformatics*, vol. 6, no. 1, p. 13, 2014.

[12] R. Xue, Z. Fang, M. Zhang, Z. Yi, C. Wen, and T. Shi, "TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis," *Nucleic Acids Research*, vol. 41, pp. D1089–D1095, 2012.

[13] W. Wang, J. Xiao, T. O. Suzek, J. Zhang, J. Wang, and S. H. Bryant, "PubMed: a public information system for analyzing bioactivities of small molecules," *Nucleic Acids Research*, vol. 37, pp. W623–W633, 2009.

[14] D. Gfeller, A. Grosdidier, M. Wirth, A. Daina, O. Michielin, and V. Zoete, "Swiss target prediction: a web server for target prediction of bioactive small molecules," *Nucleic Acids Research*, vol. 42, no. W1, pp. 32–38, 2014.

[15] P. Shannon, A. Markiel, O. Ozier et al., "Cytoscape: a software environment for integrated models of biomolecular interaction networks," *Genome Research*, vol. 13, no. 11, pp. 2498–2504, 2003.

[16] S. Marilyn, D. Irina, and A. Justin, "GeneCards version 3: the human gene integrator," *Database*, vol. 2010, 2010.

[17] J. S. Amberger, C. A. Bocchini, F. Schiettecatte, A. F. Scott, and A. Hamosh, "OMIM.org: online mendelian inheritance in man (OMIM), an Online catalog of human genes and genetic disorders," *Nucleic Acids Research*, vol. 43, no. D1, pp. D789–D798, 2014.

[18] D. Szklarczyk, A. L. Gable, D. Lyon et al., "STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets," *Nucleic Acids Research*, vol. 47, no. D1, pp. D607–D613, 2019.

[19] G. Dennis, B. T. Sherman, and D. A. Hosack, "DAVID: database for annotation, visualization, and integrated discovery," * Genome Biology*, vol. 4, no. 5, 2003.

[20] D. S. Goodsell, C. Zardecki, L. Di Costanzo et al., "RCSB protein data bank: enabling biomedical research and drug discovery," *Science*, vol. 29, no. 1, pp. 52–65, 2020.

[21] D. Seeliger and B. L. de Groot, "Ligand docking and binding site analysis with PyMOL and autodock/vina," *Journal of Computer-Aided Molecular Design*, vol. 24, no. 5, pp. 417–422, 2010.

[22] S. Forli, R. Huey, M. E. Pique, M. F. Sanner, D. S. Goodsell, and A. J. Olson, "Computational protein-ligand docking and virtual drug screening with the AutoDock suite," *Nature Protocols*, vol. 11, no. 5, pp. 905–919, 2016.

[23] K. Y. Hsin, S. Ghosh, and H. Kitano, "Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology," *PLoS One*, vol. 8, no. 12, Article ID e83922, 2013.

[24] M. J. Abraham, T. Murtola, R. Schulz et al., "GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers," *SoftwareX*, vol. 1–2, pp. 19–25, 2015.

[25] S. Pronk, S. Pöl, R. Schulz et al., "GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit," *Bioinformatics*, vol. 29, no. 7, pp. 845–854, 2013.

[26] J. Wang, R. M. Wolf, J. W. Caldwell, P. A. Kollman, and D. A. Case, "Development and testing of a general amber force field," *Journal of Computational Chemistry*, vol. 25, no. 9, pp. 1157–1174, 2004.

[27] D. A. Case, T. E. Cheatham, T. Darden et al., "The Amber biomolecular simulation programs," *Journal of Computational Chemistry*, vol. 26, no. 16, pp. 1668–1688, 2005.

[28] F. Zhang, J. Feng, J. Zhang, X. Kang, and D. Qian, "Quercetin modulates AMPK/SIRT1/FOXO signaling to inhibit inflammatory/oxidative stress responses in diabetic high fat diet-induced atherosclerosis in the rat carotid artery," *Experimental and Therapeutic Medicine*, vol. 20, no. 6, p. 1, 2020.

[29] X. I. E. Zhishen, S. O. N. G. Junying, and X. U. Jiaqian, "Mechanism of action of natural small molecular compounds in improving diabetic encephalopathy," *Chinese Journal of Diabetes*, vol. 28, no. 4, pp. 315–320, 2020.

[30] T. Xu, H. Zhu, D. Li et al., "Luteolin inhibits angiotensin II-stimulated VSMC proliferation and migration through downregulation of akt phosphorylation," *Evidence-Based Complementary and Alternative Medicine*, vol. 2015, Article ID 931782, 9 pages, 2015.

[31] H. Feng, J. Cao, G. Zhang, and Y. Wang, "Kaeempferol attenuates cardiac hypertrophy via regulation of ASK1/MITP signaling pathway and oxidative stress," *Planta Medica*, vol. 83, no. 10, pp. 837–845, 2017.

[32] Chinese Diabetes Society, "Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)," *Chinese Journal of Diabetes Mellitus*, vol. 13, no. 4, pp. 95, 2021.

[33] J. J. Ramírez-Espinosa, J. Saldaña-Ríos, S. García-Jiménez et al., "Chrysin induces anti-diabetic, antidiyslipidemic and anti-inflammatory effects in athymic nude diabetic mice," *Molecules*, vol. 23, no. 1, p. 67, 2017.

[34] T. Jain, E. A. Nikolopoulou, Q. Xu, and A. Qu, "Hypoxia inducible factor as a therapeutic target for atherosclerosis," *Pharmacology & Therapeutics*, vol. 183, pp. 22–33, 2018.
[35] Z. Hu, M. Yang, and L. Yang, “Network pharmacology-based identification of the mechanisms of Shen-Qi compound formula in treating diabetes mellitus,” Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 5798764, 15 pages, 2020.

[36] L. Maréchal, M. Laviolette, A. Rodrigue-Way et al., “The CD36-PPARc pathway in metabolic disorders,” International Journal of Molecular Sciences, vol. 19, no. 5, p. 1529, 2018.

[37] V. Tiyerili, U. M. Becher, A. Aksoy et al., “AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARc,” Cardiovascular Diabetology, vol. 12, no. 1, p. 30, 2013.

[38] A. Zmeškalová, A. Popelová, A. Exnerová, B. Železná, J. Kuneš, and L. Maletínská, “Cellular signaling and anti-apoptotic effects of prolactin-releasing peptide and its analog on SH-SY5Y cells,” International Journal of Molecular Sciences, vol. 21, no. 17, p. 6343, 2020.

[39] X. Wang, L. Gao, L. Xiao et al., “12(S)-hydroxyeicosatetraenoic acid impairs vascular endothelial permeability by altering adherens junction phosphorylation levels and affecting the binding and dissociation of its components in high glucose-induced vascular injury,” Journal of Diabetes Investigation, vol. 10, no. 3, pp. 639–649, 2019.

[40] I. Hers, E. E. Vincent, and J. M. Tavář, “Akt signalling in health and disease,” Cellular Signalling, vol. 23, no. 10, pp. 1515–1527, 2011.

[41] L. Logie, A. J. Ruiz-Alcaraz, M. Keane et al., “Characterization of a protein kinase B inhibitor in vitro and in insulin-treated liver cells,” Diabetes, vol. 56, no. 9, pp. 2218–2227, 2007.

[42] J. Chen, P. R. Somanath, O. Razorenova et al., “Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo,” Nature Medicine, vol. 11, no. 11, pp. 1188–1196, 2005.

[43] C. Fernández-Hernando, E. Ackah, J. Yu et al., “Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease,” Cell Metabolism, vol. 6, no. 6, pp. 446–457, 2005.

[44] E. Ackah, J. Yu, and S. Zoellner, “Akt1/protein kinase Bα is critical for ischemic and VEGF-mediated angiogenesis,” Journal of Clinical Investigation, vol. 115, no. 8, pp. 2119–2127, 2005.

[45] W. Li, Q. Fang, P. Zhong et al., “EGFR inhibition blocks palmitic acid-induced inflammation in cardiomyocytes and prevents hyperlipidemia-induced cardiac injury in mice,” Scientific Reports, vol. 6, no. 1, p. 24580, 2016.

[46] M. A. Reddy, S. L. Li, S. Sahar et al., “Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells,” Journal of Biological Chemistry, vol. 281, no. 19, pp. 13685–13693, 2006.

[47] C. Recio, A. Oguiza, I. Lazaro, B. Mallavia, J. Egido, and C. Gomez-Guerrero, “Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 9, pp. 1953–1960, 2014.

[48] M. Kvandová, M. Majzúnová, and J. Dovinová, “The role of PPARgamma in cardiovascular diseases,” Physiological Research, vol. 65, no. Suppl 3, pp. S343–S363, 2016.

[49] J. Chen, P. R. Somanath, O. Razorenova et al., “CEACAM1 inhibited IκB-α/NF-κB signal pathway via targeting MMP-9/TIMP-1 Axis in diabetic atherosclerosis,” Journal of Cardiovascular Pharmacology, vol. 76, no. 3, pp. 329–336, 2020.

[50] R. C. Rancourt, R. Ott, K. Schellong et al., “Visceral adipose tissue alteration of P13KR1 expression is associated with gestational diabetes but not promoter DNA methylation,” Adipocyte, vol. 8, no. 1, pp. 339–346, 2019.

[51] P. Y. Liu, R. C. Christian, M. Ruan, V. M. Miller, and L. A. Fitzpatrick, “Correlating androgen and estrogen steroid receptor expression with coronary calcification and atherosclerosis in men without known coronary artery disease,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 2, pp. 1041–1046, 2005.

[52] C. K. Huang, S. O. Lee, E. Chang, H. Pang, and C. Chang, “Androgen receptor (AR) in cardiovascular diseases,” Journal of Endocrinology, vol. 229, no. 1, pp. R1–R16, 2016.